替莫唑胺緩釋微球治療膠質(zhì)瘤皮下移植瘤的實(shí)驗(yàn)研究

《替莫唑胺緩釋微球治療膠質(zhì)瘤皮下移植瘤的實(shí)驗(yàn)研究》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。

1、910SUZHOUUVIVERSITYJOURNALOFMEDICALSCIENCE2010;30(5)替莫唑胺緩釋微球治療膠質(zhì)瘤皮下移植瘤的實(shí)驗(yàn)研究1212221吳自成，董軍，項(xiàng)朝輝，周光華，黃強(qiáng)，蘭青，吳新勇(1．江蘇省新沂市人民醫(yī)院神經(jīng)外科，江蘇新沂221400;2．蘇州大學(xué)附屬第二醫(yī)院神經(jīng)外科，江蘇蘇州215004)摘要:目的觀察替莫唑胺緩釋微球(P-TMZ)對SHG-44人腦膠質(zhì)瘤皮下移植瘤的抑瘤效應(yīng)。方法將SHG-7344膠質(zhì)瘤細(xì)胞(1×10)注射于Balb/c裸小鼠右腋皮下，再將皮下移植瘤以組織塊接種的方法皮下傳

2、代(2mm/3鼠)。待腫瘤生長至約65mm時(shí)，將荷瘤鼠隨機(jī)分為瘤內(nèi)注射替莫唑胺緩釋微球(P-TMZ)組、替莫唑胺(TMZ)組、P-TMZ+TMZ聯(lián)合用藥組、卡莫斯汀(BCNU)組、空白微球(P-0)組和生理鹽水(NS)組，每組10只鼠。將P-TMZ(500mg/kg)和P-0(500mg/kg)以DMEM培養(yǎng)液混懸至終體積150μl，經(jīng)皮多點(diǎn)穿刺緩慢注入腫瘤組織內(nèi);TMZ以50mg/kg灌胃，每日一次，連續(xù)5d;BCNU以40mg/kg尾靜脈注射一次;NS以150μl瘤內(nèi)注入。每4d測量荷瘤鼠腫瘤大小直至治療后28d。結(jié)果P-

3、TMZ、P-TMZ+TMZ和BCNU組抑瘤率均明顯高于P-0、NS組(P＜0．01)，且抑瘤效應(yīng)優(yōu)于TMZ組(P＜0．05);TMZ組抑瘤率高于P-0、NS組(P＜0．05)。結(jié)論P(yáng)-TMZ保留了TMZ的抑瘤活性，在局部應(yīng)用時(shí)抑瘤效果優(yōu)于TMZ。關(guān)鍵詞:膠質(zhì)瘤;SHG-44膠質(zhì)瘤細(xì)胞;皮下移植瘤;替莫唑胺;緩釋微球;裸小鼠中圖分類號(hào):R730．26405文獻(xiàn)標(biāo)識(shí)碼:A文章編號(hào):1673－0399(2010)05－0910－05PreliminarayStudiesonAnti-gliomaEffectofTemozolomid

4、eDelayed-ReleaseMicrospheresinSubcutaneousXenograftModel1212221WUZi-cheng，DONGJun，XIANGZhao-hui，ZHOUGuang-hua，HUANGQiang，LANQing，WUXin-yong(1．DeptofNeurosurgy，XinyiCityPeoplesHospital，JiangsuXinyi221400，China;2．DeptofNeurosurgy，the2ndHospitalAffiliatedtoSoochowUniv

5、ersity，JiangsuSuzhou215004，China)Abstract:ObjectiveToobservetheanti-gliomaeffectoftemozolomidedelayedreleasemicro-7spheresP-TMZinSHG-44subcutaneousxenograftmodel．MethodsTheSHG-44gliomacells(1×10)wereinoculatedsubcutaneouslyintotherightaxilofBalb/cnudemice．Thetumorwa

6、sresectedandcut3intopieces，andinoculatedsubcutaneously(2mm/mouse)．Whenxenografttumorsizereachedabout365mm，tumor-bearingmiceweredividedrandomlyintothe6groups(10mice/group)，namelyP-TMZgroup，TMZgroup，P-TMZplusTMZgroup，BCNUgroup，thenon-loadedmicrospheres(P-0)groupandnor

7、malsaline(NS)group．P-TMZ(500mg/kg)，andP-0(500mg/kg)weresuspendedwithDMEMtothefinalvolumeof150μlandinjectedslowlyintothetumors．TMZ(50mg/kg)wasadministeredwithgavageeverydayfor5days．BCNU(40mg/kg)wasinjectedintothetailveinonce，NSwasinjecteddi-rectly(150μl/mouse)intotum

8、ortissues．Tumorsizewasmeasuredevery4daystill28daysaftertreat-ment．ResultsTumorinhibitionratiosofP-TMZ，P-TMZplusTMZ，andBCNUweresignificantl